NasdaqCM:CLDXBiotechs
Celldex Therapeutics (CLDX) Is Down 8.3% After Barzolvolimab Misses Key Goals in EoE Trial
Celldex Therapeutics recently reported topline results from its Phase 2 study of barzolvolimab in eosinophilic esophagitis, revealing that although the drug significantly reduced mast cells, it did not improve symptoms or endoscopic outcomes compared to placebo and will not advance in this indication.
This outcome highlights the complexity of EoE and shows that effectively targeting mast cells alone may not translate to clinical benefit for patients.
We’ll now explore how halting development...